{"product_id":"thymosin-beta-4-fragment-17-23","title":"Thymosin Beta-4 Fragment 17-23","description":"\u003ch3\u003eThymosin Beta-4 Fragment 17-23 (TB-500 Fragment 17-23)\u003c\/h3\u003e\n\u003ch3\u003e1. Basic Overview\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eThymosin Beta-4 Fragment 17–23 (commonly known as TB-500) is a synthetic acetylated heptapeptide. It corresponds to amino acid residues 17–23 of endogenous full-length Thymosin Beta-4 (Tβ4).\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAmino Acid Sequence:\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eAc-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH (Ac-LKKTETQ)\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCAS Number: 885340-08-9\u003c\/li\u003e\n\u003cli\u003eMolecular Weight: 889.01 Da\u003c\/li\u003e\n\u003cli\u003eForm: Lyophilized white crystalline powder\u003c\/li\u003e\n\u003cli\u003eCore Feature: This short fragment contains the\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eactin-binding domain\u003c\/strong\u003e, the primary functional motif responsible for most of Tβ4’s tissue regeneration activity. It is easier to synthesize, purify and cost-effective compared to full-length Thymosin Beta-4.\u003c\/li\u003e\n\u003cli\u003eNote: It is not naturally produced in the human body; it is a synthetic truncated peptide developed for research.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e2. Mechanism of Action\u003c\/h3\u003e\n\u003col\u003e\n\u003cli\u003eHigh-affinity binding to monomeric globular actin (G-actin), regulating actin polymerization and cytoskeleton remodeling.\u003c\/li\u003e\n\u003cli\u003ePromotes keratinocyte, fibroblast and endothelial cell migration, a critical step for wound closure and tissue regeneration.\u003c\/li\u003e\n\u003cli\u003eStimulates angiogenesis (new blood vessel formation) at injury sites to improve nutrient supply for damaged tissue.\u003c\/li\u003e\n\u003cli\u003eModulates local inflammatory response, reduces excessive inflammatory cell infiltration and limits pathological scar tissue formation.\u003c\/li\u003e\n\u003cli\u003eFacilitates recruitment of progenitor\/stem cells to damaged regions to accelerate musculoskeletal and soft tissue repair.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cdiv\u003eKey difference vs full-length Thymosin Beta-4: Fragment 17-23 only retains actin-binding \u0026amp; cell migration activity. Full-length Tβ4 contains extra domains with independent anti-fibrotic and cardioprotective effects. Fragment 17-23 has a shorter biological half-life.\u003c\/div\u003e\n\u003ch3\u003e3. Main Research Applications\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eSoft tissue wound healing, acute \u0026amp; chronic skin injury models\u003c\/li\u003e\n\u003cli\u003eTendon, ligament and skeletal muscle damage regeneration research\u003c\/li\u003e\n\u003cli\u003eAngiogenesis and vascular tissue repair studies\u003c\/li\u003e\n\u003cli\u003eAnti-scarring and extracellular matrix remodeling experiments\u003c\/li\u003e\n\u003cli\u003eOcular epithelial wound recovery research\u003c\/li\u003e\n\u003cli\u003eComparative pharmacology: Full-length Tβ4 vs bioactive fragment screening\u003c\/li\u003e\n\u003cli\u003eCombined therapy research with regenerative peptides (BPC-157, GHK-Cu)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e4. Reconstitution Instructions (Lyophilized Vial)\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eCommon specification: \u003c\/span\u003e\u003cstrong\u003e5mg \/ 10mg per vial\u003c\/strong\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003eLet peptide vial reach room temperature; disinfect rubber stopper with alcohol.\u003c\/li\u003e\n\u003cli\u003eSlowly inject Bacteriostatic Water along the inner glass wall. Avoid direct impact onto lyophilized powder.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cdiv\u003eStandard mixing scheme: 10mg powder + 2mL BAC water → Concentration = 5 mg\/mL\u003c\/div\u003e\n\u003col start=\"3\"\u003e\n\u003cli\u003eGently rotate the vial to dissolve powder.\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eDO NOT shake violently to avoid peptide aggregation and degradation.\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eQualified solution is clear and colourless.\u003c\/li\u003e\n\u003cli\u003eStorage Requirements\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cul\u003e\n\u003cli\u003eUnreconstituted lyophilized powder: Hermetically sealed, stored at -20°C, protected from light. Stable for up to 24 months.\u003c\/li\u003e\n\u003cli\u003eReconstituted peptide solution: Refrigerate 2°C ~ 8°C, stable within 28 days.\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eDo not freeze reconstituted liquid.\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e5. Research Administration Protocols\u003c\/h3\u003e\n\u003ch3\u003ePrimary Route: Subcutaneous Injection\u003c\/h3\u003e\n\u003ch3\u003eReference Experimental Dosage (Extrapolated from preclinical models)\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eLoading experimental phase:\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e400–750 mcg, 2–3 times weekly for 2–3 weeks\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eMaintenance experimental phase:\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e200–400 mcg, 1–2 times weekly\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eafter visible tissue recovery response\u003c\/li\u003e\n\u003cli\u003eInjection site: Abdomen, thigh or around localized injury sites; rotate injection positions regularly.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eReference Experimental Cycle\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eContinuous research administration for maximum 6–8 weeks, pause at least 4 weeks before starting a new experimental cycle.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e6. Precautions \u0026amp; Observed Adverse Reactions\u003c\/h3\u003e\n\u003col\u003e\n\u003cli\u003ePure laboratory research compound. Not authorized for human therapeutic use.\u003c\/li\u003e\n\u003cli\u003eStrict aseptic technique required during reconstitution to prevent microbial contamination.\u003c\/li\u003e\n\u003cli\u003eDiscard solution immediately if turbidity, precipitation or discoloration appears.\u003c\/li\u003e\n\u003cli\u003eCommon mild observed effects: slight redness, itching or tenderness at injection site. Systemic adverse reactions are rare within standard experimental doses.\u003c\/li\u003e\n\u003cli\u003eLimited long-term high-dose safety data available. Avoid prolonged continuous exposure.\u003c\/li\u003e\n\u003cli\u003eDo not confuse Fragment 17-23 with full-length Thymosin Beta-4; biological activity spectrum and pharmacokinetics are not identical.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr\u003e\n\u003ch3\u003eShort Version (For Product Page \/ Customer Direct Message)\u003c\/h3\u003e\n\u003ch3\u003eThymosin Beta-4 Fragment 17-23 (TB-500)\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eThymosin Beta-4 Fragment 17-23 is a synthetic acetylated heptapeptide containing the core actin-binding domain of endogenous Thymosin Beta-4. It regulates actin dynamics, accelerates cell migration and angiogenesis, and is widely used for wound healing, tendon\/muscle injury regeneration and anti-scarring laboratory research.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003eReconstitution\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eMix lyophilized powder with bacteriostatic water. Rotate gently; avoid violent shaking. Reconstituted solution must be refrigerated and used within 28 days.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003eReference Subcutaneous Research Dosage\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003e200–750 mcg per injection, 1–3 times weekly. Loading phase is recommended for acute injury research models.\u003c\/span\u003e\u003c\/p\u003e","brand":"我的商店","offers":[{"title":"5mg*10vials","offer_id":53703767097644,"sku":null,"price":31.0,"currency_code":"USD","in_stock":true},{"title":"10mg*10vials","offer_id":53703767130412,"sku":null,"price":33.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0979\/1406\/1100\/files\/549f18b0f5f6978704b09c024a047fb03816f964f889efb20b481d213ee78ec0.png?v=1786602882","url":"https:\/\/0rw2.com\/products\/thymosin-beta-4-fragment-17-23","provider":"0rw2.com","version":"1.0","type":"link"}